294 related articles for article (PubMed ID: 34615513)
21. Involvement of YAP, TAZ and HSP90 in contact guidance and intercellular junction formation in corneal epithelial cells.
Raghunathan VK; Dreier B; Morgan JT; Tuyen BC; Rose BW; Reilly CM; Russell P; Murphy CJ
PLoS One; 2014; 9(10):e109811. PubMed ID: 25290150
[TBL] [Abstract][Full Text] [Related]
22. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
23. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases.
Yu Y; Su X; Qin Q; Hou Y; Zhang X; Zhang H; Jia M; Chen Y
Pharmacol Res; 2020 Sep; 159():105009. PubMed ID: 32553712
[TBL] [Abstract][Full Text] [Related]
24. YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.
Lu X; Peng B; Chen G; Pes MG; Ribback S; Ament C; Xu H; Pal R; Rodrigues PM; Banales JM; Evert M; Calvisi DF; Chen X; Fan B; Wang J
Am J Pathol; 2021 Sep; 191(9):1651-1667. PubMed ID: 34129844
[TBL] [Abstract][Full Text] [Related]
25. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
27. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
28. [YAP induces chromosomal instability in liver cancer patients].
Weiler S
Pathologe; 2018 Dec; 39(Suppl 2):185-188. PubMed ID: 30206654
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
30. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
31. SAHA induce hippo pathway in CCA cells without increasing cell proliferation.
Özel M; Başkol G; Başkol M; Güneş F; Uçar Ç; Doğru BN; Akalın H
Mol Biol Rep; 2022 May; 49(5):3649-3656. PubMed ID: 35112301
[TBL] [Abstract][Full Text] [Related]
32. Deregulation of Hippo kinase signalling in human hepatic malignancies.
Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
[TBL] [Abstract][Full Text] [Related]
33. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
34. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
35. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
36. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
[TBL] [Abstract][Full Text] [Related]
38. YAP and the Hippo pathway in cholangiocarcinoma.
Sugihara T; Isomoto H; Gores G; Smoot R
J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
[TBL] [Abstract][Full Text] [Related]
39. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
[TBL] [Abstract][Full Text] [Related]
40. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
